Key result
L-asparaginase linked to reversible ~41% increase in serum cholesterol in pediatric acute lymphoblastic leukemia.
Why the study?
Abnormal blood lipid profiles have been associated with many malignant diseases, especially in children with acute lymphoblastic leukemia on L-asparaginase therapy.
Does L-asparaginase therapy alter lipid profiles in children with acute lymphoblastic leukemia?
Observational (n=30)
No
Does L-asparaginase therapy alter lipid profiles in children with acute lymphoblastic leukemia?
Absolute Event Rate: 222.3% vs 158%
p-value: p=<0.001
L-asparaginase therapy in children with acute lymphoblastic leukemia causes significant, reversible elevations in cholesterol and triglycerides during the induction phase.
Transient hyperlipidemia during L-asparaginase in pediatric ALL may warrant monitoring; leaves open its clinical sequelae and management needs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Janan Ghalib Hasan (2010) conducted an observational in Acute Lymphoblastic Leukemia (n=30). L-asparaginase therapy vs. Baseline (before therapy) and after therapy was evaluated on Mean serum cholesterol (CH) and triglycerides (TG) (p=<0.001). L-asparaginase therapy significantly increased mean serum cholesterol (from 158 to 222.3 mg/dl) and triglycerides (from 119.4 to 223.1 mg/dl) in children with acute lymphoblastic leukemia, which reversed after discontinuation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: